People on the Move
Essa Pharma
Essa Pharma has appointed financial advisor Franklin Berger to its board of directors.
The company is developing a treatment for prostate cancer based on blocking the N-terminal domain of the androgen receptor.
Essa’s molecule – EPI-506 – targets metastatic castration-resistant prostate cancer patients who have failed current hormone therapies. A clinical trial and an Investigational New Drug application is planned to begin soon.
New director Berger is a resident of New York, and has a background in strategic advisory work with venture capital firms and biopharmaceutical companies. He spent 12 years in sell-side equity research, most recently as MD of US Equity Research at J. P. Morgan until 2003.
Richard Glickman, Essa Chairman, welcomed Berger to the Board. “As an investor in ESSA, he has a serious stake in our success. As a deeply experienced strategic advisor, he will bring an invaluable perspective to our strategy decisions.”
